Clinical Report: FDA Label Update for Primary CNS Lymphoma

Overview

Dana-Farber-led research has resulted in an FDA label update for axicabtagene ciloleucel, removing the exclusion for patients with primary central nervous system lymphoma. This change is expected to enhance access to CAR T-cell therapy for eligible patients with relapsed or refractory disease.

Background

Primary central nervous system lymphoma (PCNSL) is a rare and aggressive form of lymphoma that affects the brain and spinal cord. Historically, patients with CNS involvement were excluded from CAR T-cell therapy trials due to concerns about neurologic toxicity. The recent FDA label update reflects a significant shift in treatment options for this challenging patient population.

Data Highlights

No numerical data provided in the source material.

Key Findings

• The FDA updated the label for axicabtagene ciloleucel to include patients with relapsed or refractory PCNSL.
• Prior to this update, patients with CNS involvement were excluded from CAR T-cell therapy trials due to neurotoxicity concerns.
• The Dana-Farber pilot study demonstrated the safety and feasibility of CAR T-cell therapy in this population.
• Approximately half of the treated patients were alive and without relapse at around one year, indicating potential efficacy.
• Longer follow-up is necessary to assess long-term remission rates in this patient group.

Clinical Implications

The removal of the exclusion for PCNSL patients from CAR T-cell therapy opens new treatment avenues for those with limited options. Clinicians should consider this updated indication when evaluating treatment plans for eligible patients with relapsed or refractory CNS lymphoma.

Conclusion

The FDA's label update for axicabtagene ciloleucel marks a significant advancement in the treatment of primary CNS lymphoma, potentially improving outcomes for affected patients. Ongoing research and follow-up will be essential to fully understand the long-term benefits of this therapy.

References

1. Gilead Sciences, Inc., FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma, 2026 -- FDA Approval Announcement
2. Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, European Hematology Association, 2024 -- Clinical Practice Guideline
3. The ASCO Post — Selected Abstracts From the 2016 ASH Annual Meeting
4. The ASCO Post — Recent FDA Drug Approvals Foster Growing Treatment Armamentarium for Chronic Lymphocytic Leukemia and Rare B-Cell Lymphomas
5. dana-farber — Triplet Therapy Shows Promise for BPDCN, a rare blood cancer, in Dana-Farber Study
6. The ASCO Post — Novel Therapies and New Indications for Use in Treatment of Hematologic Malignancies
7. Clinical trials show promise in treating central nervous system lymphoma, breast cancer, and glioblastoma | Dana-Farber Cancer Institute
8. Gilead Sciences, Inc. - FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma
9. Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up - The European Hematology Association (EHA)